With kids back in school, pediatric viral illnesses are revving their engines. It seems we have returned to normal seasonality for viral disease after the coronavirus pandemic. Top of mind with the arrival of fall is respiratory syncytial virus (RSV). We know how quickly the onset of RSV season can take over our waiting rooms.  

Last year, two important developments occurred that could change the course of RSV prevention: the FDA approval of a maternal vaccine and a monoclonal antibody for infants. Far too few mothers and infants benefitted from these treatments during last year’s respiratory season, but now we’ve had a year to prepare to do better.

Joining us to discuss this hot topic are two expert pediatricians. Sean O’Leary, MD, is an Infectious Disease Physician at Children’s Hospital Colorado, a Professor of Pediatrics at the University of Colorado School of Medicine and is the chair of the American Academy of Pediatrics Committee on Infectious Diseases, also known as the Red Book Committee. Matt Dorighi, MD, specializes in pediatrics at Cherry Creek Pediatrics. He is currently chair of the Pediatric Care Network, the largest clinically integrated network for children in the state of Colorado.  

Some highlights from this episode include: 

• Guidelines for Nirsevimab and the maternal vaccine 
• Why availability will not be a barrier this respiratory season 
• How practices can combat vaccine hesitancy 

For more information on Children’s Colorado, visit: childrenscolorado.org.